Rat Interleukin 33 (IL33) Protein

Product specifications

Proteins and Peptides

Interleukin 33 (IL33)

E. coli

Rat

Unconjugated

Molecular Weight: Calculated MW: 13.1 kDa
Concentration: Prior to lyophilization: 200 µg/ml
Sequence Fragment: Met5-Leu108
Tag: N-terminal His tag

Recombinant

> 95%

10 µg

50 µg

100 µg

200 µg

500 µg

Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.

WB, SDS-PAGE

Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 1 mM DTT, 5% Trehalose and Proclin-300.

Shipped within 5-7 working days.

Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.

No

Q66H70

IL33,IL-33,C9orf26,IL1F11,IL-1F11

Protein IL33

RUO

This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

IL33 is a nuclear alarmin cytokine belonging to the IL-1 family, released during cellular stress, injury, or necrosis to alert the immune system and promote inflammation. IL33 binds to its receptor IL1RL1 (ST2) and forms a signaling complex with IL1RAP, leading to activation of NF-κB and MAPK pathways, which drive cytokine production, immune cell activation, and tissue repair. IL33 primarily targets type 2 immune cells, including Th2 cells, innate lymphoid cells (ILC2s), mast cells, and eosinophils, to regulate allergic inflammation, tissue homeostasis, and anti-helminth immunity. It is abundantly expressed in epithelial cells, endothelial cells, and fibroblasts, where it functions as both a cytokine and a transcriptional regulator. Dysregulated IL33 signaling contributes to allergic diseases, such as asthma, atopic dermatitis, and rhinitis, as well as inflammatory and fibrotic disorders. In tumors, IL33 can promote both pro- and anti-tumor immune responses depending on the context. Knockout studies reveal reduced type 2 cytokine production, impaired tissue repair, and weakened immune responses, highlighting IL33’s role in inflammation, tissue homeostasis, and immunity.

Related Products

Human IL-33(Interleukin-33) ELISA Kit

Ver Producto

Mouse IL-33(Interleukin 33) ELISA Kit

Ver Producto

Rat IL-33(Interleukin-33) ELISA Kit

Ver Producto